Daewoong Pharmaceutical Co. Ltd.

This study tested a new three-drug combination (DWP14012-based triple therapy) against a standard treatment to see if it can safely and effectively eliminate Helicobacter pylori, a bacteria that can cause stomach ulcers. 461 adults with confirmed H. pylori infection took part. Th…

This study tested whether giving two drugs together (DWC202206 and DWC202207) is safe and effective for people who have both high blood pressure and high cholesterol. 214 adults aged 19 to 80 took part. The main goals were to see if the combination lowered blood pressure and LDL …

This study tested whether adding a third drug (DWC202314) to a two-drug combination (DWC202405/DWC202313) helps lower blood pressure more effectively in people whose high blood pressure is not well controlled with the two-drug combo alone. The trial involved 198 adults with essen…

This study tested whether adding a second drug (DWC202314) to an existing one (DWC202404) helps lower blood pressure in people whose hypertension is not well controlled with the first drug alone. 192 adults with essential hypertension took part. The main goal was to see how much …

This study observed over 2,800 adults with erosive gastroesophageal reflux disease (GERD) who took FEXUCLUE tablets. Researchers measured how much heartburn and reflux symptoms improved after 4 to 8 weeks using patient questionnaires. The goal was to see if the drug eases discomf…

This study looked at how two experimental drugs (DWC202511 and DWC202512) change the way the body processes another drug (DWP16001) in healthy adults. 18 volunteers took part to measure drug levels and safety. The goal was to gather information, not to treat any disease.

This study tested whether two drugs, DWJ1445 and DWC202506, are absorbed into the body in the same way. It involved 70 healthy adults who received a single dose of each drug at different times. The goal was to check bioequivalence, not to treat any disease.